SL-325

N/A

Report date: 2026/05/02 20:00:18

First In Class

Base Information

Drug NameSL-325

Drug Alias NameSL-325

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody

Mechanisms of ActionTumor necrosis factor receptor superfamily member 25 antagonists

TargetsTumor necrosis factor receptor superfamily member 25

Therapy Area/IndicationsInflammatory Bowel Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesShattuck Labs Inc

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsInflammatory Bowel Diseases

Inactive IndicationsN/A

ATC CodeN/A